Abstract
Exhaled nitric oxide (NO) level decreases after corticosteroid treatment in asthmatics, but the effect of a leukotriene receptor antagonist, pranlukast, on exhaled NO has not been elucidated. Pranlukast treatment in mild persistent asthmatics for 4 weeks decreased the exhaled NO level, which did not differ from the levels in healthy subjects.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Anti-Asthmatic Agents / administration & dosage*
-
Asthma / drug therapy*
-
Asthma / metabolism*
-
Chromones / administration & dosage*
-
Female
-
Humans
-
Leukotriene Antagonists* / administration & dosage*
-
Male
-
Middle Aged
-
Nitric Oxide / metabolism*
-
Receptors, Leukotriene / metabolism
Substances
-
Anti-Asthmatic Agents
-
Chromones
-
Leukotriene Antagonists
-
Receptors, Leukotriene
-
Nitric Oxide
-
pranlukast